FDA is a ticker tracked in our intelligence system with 5 linked articles.
BillionToOne goes public as YCâs fourth biotech IPO, boasting that 1 in 11 US babies are tested with its fetal DNA test, with rapid development from YC and a track record of FDA-cleared Covid testing and a 2023 cancer/liquid biopsy product, underscoring regulatory and execution advantages despite promotional framing.
FDA approved a new sunscreen ingredient; article promises four key takeaways.
TechCrunch Mobility blends a high-profile EV critique (Ferrari Luce) with regulatory and funding dynamics in mobility and AI, anchored by hard data points like AV registrations, deal sizes, and regulatory shifts.
US Black-founded startups have raised a record $643M in 2026 year-to-date amid a funding downturn, driven by a few large rounds, while regulatory shifts around peptides (FDA advisory committee in July 2026) could reshape the opportunity set.
TechCrunch dissectes Enhanced Games and the wider peptide/health enhancement trend, highlighting a $1.2B IPO, a $50M venue, and high-prize, high-risk athletic and regulatory dynamics driven by Silicon Valley backing.
TechCrunch coverage spans a Snap alumni fund (Ghost Angels) and several regulatory and macro-trends in AI, fintech, and digital advertising, with notable hard data on fund sizes, valuations, and product economics.
Subscribe for real-time ticker updates and unlimited access to our intelligence platform.